JP2024516619A5 - - Google Patents
Info
- Publication number
- JP2024516619A5 JP2024516619A5 JP2023565163A JP2023565163A JP2024516619A5 JP 2024516619 A5 JP2024516619 A5 JP 2024516619A5 JP 2023565163 A JP2023565163 A JP 2023565163A JP 2023565163 A JP2023565163 A JP 2023565163A JP 2024516619 A5 JP2024516619 A5 JP 2024516619A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antibody
- composition
- optionally
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177956P | 2021-04-21 | 2021-04-21 | |
| US63/177,956 | 2021-04-21 | ||
| PCT/US2022/025651 WO2022226130A1 (en) | 2021-04-21 | 2022-04-20 | Methods of treatment and dosing of natural killer cell compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516619A JP2024516619A (ja) | 2024-04-16 |
| JP2024516619A5 true JP2024516619A5 (cg-RX-API-DMAC7.html) | 2025-09-04 |
Family
ID=81648459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565163A Pending JP2024516619A (ja) | 2021-04-21 | 2022-04-20 | 治療方法及びナチュラルキラー細胞組成物の投与方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240197783A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326288A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024516619A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240111702A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117915927A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022262606A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216410A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022226130A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117187181B (zh) * | 2023-11-08 | 2024-03-19 | 普华赛尔生物医疗科技有限公司 | 包被组合物的方法及其应用 |
| WO2025245399A1 (en) * | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
| CN119193483A (zh) * | 2024-11-26 | 2024-12-27 | 北京国卫生物科技有限公司 | 一种体外高效扩增nk细胞的培养方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6168991B1 (en) | 1999-06-25 | 2001-01-02 | Lucent Technologies Inc. | DRAM capacitor including Cu plug and Ta barrier and method of forming |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| RS53263B (sr) | 2006-08-14 | 2014-08-29 | Xencor Inc. | Optimizovana antitela usmerena na cd19 |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2012061814A1 (en) | 2010-11-05 | 2012-05-10 | Transgenomic, Inc. | Pcr primers and methods for rapid and specific genotyping |
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| WO2016122014A1 (ko) * | 2015-01-27 | 2016-08-04 | 한국생명공학연구원 | 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도 |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下製剤及びその使用 |
| EP3487991B1 (en) * | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| CN112839666A (zh) * | 2018-05-14 | 2021-05-25 | 因达普塔治疗公司 | 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群 |
| MA53920A (fr) * | 2018-10-17 | 2021-09-15 | Janssen Biotech Inc | Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 |
| EP3884041A2 (en) * | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| US20200308297A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
| SG11202113092WA (en) | 2019-06-10 | 2021-12-30 | Adc Therapeutics Sa | Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent |
-
2022
- 2022-04-20 US US18/556,333 patent/US20240197783A1/en active Pending
- 2022-04-20 WO PCT/US2022/025651 patent/WO2022226130A1/en not_active Ceased
- 2022-04-20 CN CN202280041765.2A patent/CN117915927A/zh active Pending
- 2022-04-20 JP JP2023565163A patent/JP2024516619A/ja active Pending
- 2022-04-20 AU AU2022262606A patent/AU2022262606A1/en active Pending
- 2022-04-20 CA CA3216410A patent/CA3216410A1/en active Pending
- 2022-04-20 KR KR1020237039564A patent/KR20240111702A/ko active Pending
- 2022-04-20 EP EP22723284.0A patent/EP4326288A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hadiloo et al. | CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy | |
| Liu et al. | NK cell-based cancer immunotherapy: from basic biology to clinical development | |
| Lamb et al. | Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future | |
| US12060577B2 (en) | Compositions for expanding natural killer cells | |
| Sutlu et al. | Natural killer cell‐based immunotherapy in cancer: current insights and future prospects | |
| Song et al. | IL‐12/IL‐18‐preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation | |
| CN113383071A (zh) | 用于t细胞工程化的组合物和方法 | |
| Torelli et al. | Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission | |
| Servais et al. | Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
| Baiocchi et al. | GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder | |
| US20210008110A1 (en) | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions | |
| Burns et al. | Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer | |
| Gassner et al. | Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia | |
| WO2005009466A1 (en) | Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells | |
| Maeda | Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide | |
| Caruso et al. | NK cells as adoptive cellular therapy for hematological malignancies: advantages and hurdles | |
| F Krakow et al. | Do we need full donor chimerism? How alloreactive cell therapies without substantial engraftment might treat hematologic cancers | |
| Meehan et al. | Adoptive cellular therapy using cells enriched for NKG2D+ CD3+ CD8+ T cells after autologous transplantation for myeloma | |
| CN115768880A (zh) | 用于t细胞工程化的组合物和方法 | |
| Wendelboe et al. | Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy? | |
| Janakiram et al. | Novel cell and immune engagers in optimizing tumor-specific immunity post-autologous transplantation in multiple myeloma | |
| KR102032384B1 (ko) | 제대혈 단핵세포에서의 자연살해세포의 제조 방법 | |
| KR102623065B1 (ko) | 자연 살해 세포의 생체 내 프라이밍 | |
| JP2020534252A (ja) | Nk−92細胞を用いた白血病の治療と抑制 | |
| Gillgrass et al. | Recent Advances in the Use of NK Cells Against Cancer |